News

The results suggest that BACE-1 inhibitors, while a promising option to slow progression of Alzheimer disease, require further study with careful safety monitoring.

After Theranica’s remote electrical neuromodulation was approved for those aged 12 years and older with migraine, study investigator Jennifer McVige, MD, MA, shared her insight.

The director of the Parkinson’s Disease and Movement Disorder Program at Emory University School of Medicine explained the various factors that make Parkinson so difficult to manage.

Data suggest that treatment-emergent adverse events with adjunctive brivaracetam increased in incidence by number of lifetime AEDs.

The basis of the approval for peginterferon beta-1a was from a phase 1 crossover study that showed the drug’s bioequivalence to subcutaneous injection.

The neurologist from Cleveland Clinic discussed perampanel’s unique mechanism of action.

Here's what is coming soon to NeurologyLive.

The director of the Dartmouth Epilepsy Program discussed a few of the notable highlights and themes from the recently completed American Epilepsy Society Annual Meeting.

Jude Savarraj, PhD, discusses the accurate performance of his team’s machine learning models in predicting subarachnoid hemorrhage outcomes.

The director of the Massachusetts General Hospital ALS Care Center discussed the origins of ‘The Data is Here’ campaign and the reason to launch it now.

Clinically relevant scores of 32 and 44 on the Fugl-Meyer Motor Score were documented in 2 patients who received NSI-566.

Neurology News Network for the week ending January 30, 2021.

The study also found that patients with PD that used telehealth for mental health services were less likely to prefer telehealth over in-office visits.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 29, 2021.

The investigational agent developed by Biogen and Eisai is now expected to receive regulatory review by June 7, 2021.

The observed increase in QOLIE-31 scores for patients with refractory disease was driven by increases on the energy-fatigue domain.

The director of the Montefiore Headache Center discussed his hopes that rimegepant will be approved as a preventive treatment of migraine.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive conversation between an expert neurologist, psychologist, patient, and care partner on various facets of multiple sclerosis.

The primary investigator of the phase 4 RESPOND study discussed the role that postmarketing studies can play in assessing treatments for SMA.

Valproic acid’s efficacy as a monotherapy is complicated by its previously demonstrated unsuitability for pregnant women.

Specific health-related quality of life measures in physical activities, well-being, cognition, and social activities were improved among those who underwent the laser ablation procedure.

Brian Frederick, PhD, discusses how the short life expectancy after diagnosis leads many patients with ALS to lose their lives before receiving disability benefits.

Biohaven executives remain optimistic about the slight but insignificant improvement observed in those with mild AD.

The clinical fellow at Massachusetts General Hospital gives his call to action on how what needs to change to improve EEG education among residency programs.

Relapse, followed by medication history and age, was among the highest exclusion rates for MS trials across different disease-modifying therapies.

Creative Medical Technology’s ImmCelz contrasts other stem cell-based approaches by utilizing stem cells outside of the body to reprogram the patient’s own immune cells.

Researchers hope that R-loop modulation may hold potential in the future treatment of ALS.